MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
21 mai 2020 16h05 HE
|
MacroGenics, Inc.
Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
13 mai 2020 17h10 HE
|
MacroGenics, Inc.
Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
05 mai 2020 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
29 avr. 2020 16h01 HE
|
MacroGenics, Inc.
Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
28 avr. 2020 16h01 HE
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
28 avr. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
27 avr. 2020 00h05 HE
|
MacroGenics, Inc.
Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Departure of Chief Medical Officer
04 mars 2020 17h00 HE
|
MacroGenics, Inc.
Rockville, MD, March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
27 févr. 2020 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
25 févr. 2020 16h01 HE
|
MacroGenics, Inc.
Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancerFirst clinical data...